Ask AI
ProCE Banner Activity

ExpressPoints
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Slideset Download

Download this short summary slideset of key takeaway points from a live presentation on the latest data on treatment for patients with HR+/HER2- early breast cancer.

Released: July 09, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Stephen R. D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom

Sara M. Tolaney, MD, MPH

Chief, Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, Artios Pharma, Arvinas, AstraZeneca, Atkis Oncology, Avenzo Therapeutics, Bayer, BeOne Therapeutics, Bicycle Therapeutics, BioNTech, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb/Systimmune, Celcuity, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR, Eisai, Gilead, GNE/Roche, Hengrui USA, Jazz, Johnson & Johnson/Ambrx, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Pfizer/SeaGen, Reveal Genomics, Sumitovant Biopharma, Summit Therapeutics, Tango Therapeutics, Zuellig Pharma; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer/SeaGen; other financial or material support: Arvinas, Gilead, Jazz, Lilly, Pfizer, Roche.